Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
10 valent pneumococcal conjugate vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 10 valent pneumococcal conjugate vaccine | BIOLOGICAL | - |
| Infanrix Hexa | BIOLOGICAL | - |
| Rotarix | BIOLOGICAL | - |
| Paracetamol | DRUG | - |
Inclusion Criteria: * Healthy children 9-16 weeks old and born after a gestation of at least 36 weeks. Exclusion Criteria: * Body weight \< 4.5 kg * Children having received or planning to receive any investigational or non-registered products, vaccines not foreseen in the protocol, and immune mo...
The 10-valent pneumococcal conjugate vaccine is used to prevent infections caused by Streptococcus pneumoniae. It is being studied in healthy infants and toddlers to assess its safety and immunogenicity when given as a booster dose or alongside standard infant vaccines.
The 10-valent pneumococcal conjugate vaccine is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK.
The 10-valent pneumococcal conjugate vaccine is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved for public use and is still undergoing clinical trials to evaluate its safety and effectiveness.
The 10-valent pneumococcal conjugate vaccine has completed two Phase 3 trials. One trial, NCT00370227, studied a booster dose in 390 children in Finland. Another trial, NCT00370318, evaluated prophylactic antipyretic treatment in 400 children receiving the vaccine with standard infant vaccines in Czechia.
The 10-valent pneumococcal conjugate vaccine targets Streptococcus pneumoniae, the bacterium responsible for pneumococcal infections. It is designed to elicit an immune response against this pathogen to help prevent related diseases.